Xero (ASX:XRO) fell 8% after FY26 results as Melio weighed on margins, but organic growth and US revenue still support the turnaround case.
Growth Stocks
Zip Co Shares Drop on Forced Rebrand
Zip Co (ASX:ZIP)Â shares dropped as much as 5% on Wednesday after the High Court ruled against the company in a long-running trademark fight with non-bank lender Firstmac. Zip now has just 28 days to stop using the "Zip" name in Australia, meaning a full rebrand of its local…
Macquarie’s result for FY26 landed with the kind of force that tends to dominate headlines. A 30% jump in net profit to $A4.8bn, a record second half, and a return on equity rising to 14% created an understandable sense of momentum.
Yet the real story sits beneath the headline numbers. FY26 was a year shaped by…
A hidden deep tech portfolio with a free option on growth
Powerhouse Ventures (ASX:PVL) is an A$18.6 million deep tech portfolio that most investors have not noticed yet.
PVL is now rebuilding itself around a deep tech portfolio growing at 30% per half, an advisory business starting to scale, and a new fund that could re-rate…
Decidr AI Industries (ASX:DAI) raised A$15m to fund Sugarwork productisation, agentic AI expansion and sovereign compute plans.
HMC Capital (ASX:HMC) reaffirmed FY26 guidance while simplifying its platform around recurring earnings and high ROE growth.
Gentrack (ASX:GTK) cut FY26 revenue guidance while signalling a NZ$20m buyback and stronger recurring revenue growth.
When will we see hydrogen in Australia? Not as a fad, not as an idea, but as a widespread energy source as we are all being told it will be? Earlier this decade, you could be forgiven for thinking the answer was very soon — billions were being pledged, projects were multiplying, and major companies…
For every one of the ASX Biotech Success Stories, there are several failures. While a handful of companies can and do convert clinical data into extraordinary value, many others run into the barrier that decides everything: the primary endpoint.
The successes tend to follow a recognisable pattern — a credible clinical signal, external validation, and either…
DUG Technology (ASX:DUG) grew Q3 revenue 35%, lifted EBITDA 49% and moved into net cash as software and HPC revenue scaled.
